| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000021555 |
| Receipt No. | R000024834 |
| Official scientific title of the study | Safety and efficacy of polyphosphate for the treatment of ulcerative colitis(AMU002-CR01) |
| Date of disclosure of the study information | 2016/03/31 |
| Last modified on | 2018/09/25 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Safety and efficacy of polyphosphate for the treatment of ulcerative colitis(AMU002-CR01) | |
| Title of the study (Brief title) | Safety and efficacy of polyphosphate for the treatment of ulcerative colitis(AMU002-CR01) | |
| Region |
|
|
| Condition | |||
| Condition | Ulcerative colitis | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To assess the safety and efficacy of polyphosphate in the treatment of ulcerative colitis |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Frequency and grade of adverse events due to 4-week administration of polyphosphate for the treatment of ulcerative colitis |
| Key secondary outcomes | Efficacy of 4-week administration of polyphosphate for improvements in clinical and histological inflammation and the expressions of pro-inflammatory cytokines in the treatment of ulcerative colitis |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral administration of polyphosphate
Step 1 300mg/day of polyphosphate, after meal in the mornig everyday for 28 days Step 2 1000mg/day of polyphosphate, after meal in the morning everyday for 28 days |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with refractory ulcerative colitis (Mayo score, 3 to 8; rectal bleeding score, 1 or more; endoscopic subscore, 2 or more) | |||
| Key exclusion criteria | Patients with drug allergies, renal failure, liver dysfunction, malignancies, pregnancy, history of bowel surgery, infectious colitis, irritable bowel disease, hyperthyroidism or hyperphosphatemia
Patients who are judged to be ineligible by the chief study conductor or doctor in charge |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Mikihiro Fujiya |
| Organization | Asahikawa Medical University |
| Division name | Division of Gastroenterology and Hematology/Oncology, Department of Medicine |
| Address | 2-1-1-1, Midorigaoka-higashi, Asahikawa, Hokkaido, Japan |
| TEL | 81-166-68-2462 |
| fjym@asahikawa-med.ac.jp | |
| Public contact | |
| Name of contact person | Mikihiro Fujiya |
| Organization | Asahikawa Medical University |
| Division name | Division of Gastroenterology and Hematology/Oncology, Department of Medicine |
| Address | 2-1-1-1, Midorigaoka-higashi, Asahikawa, Hokkaido, Japan |
| TEL | 81-166-68-2462 |
| Homepage URL | |
| fjym@asahikawa-med.ac.jp | |
| Sponsor | |
| Institute | Asahikawa Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024834 |